A novel technique using three-dimensionally documented biopsy mapping allows precise XXXX foci with serial surveillance of cell cycle progression gene panel.

@entity5 @entity1 @entity263 @entity3457
BACKGROUND: Conventional systematic biopsy has the shortcoming of sampling error and reveals "no evidence of @entity5 " with a rate of >50% on @entity3457 ( @entity3457 ). The objective of this study is to report our initial experience of applying a 3D-documented biopsy-mapping technology to precisely re-visit geographically documented @entity263 and to perform serial analysis of cell-cycle-progression (CCP) gene-panel. METHODS: Over a period of 40 months (1/2010-4/2013), the 3D-biopsy-mapping technique, in which the spatial location of biopsy-trajectory was digitally recorded (Koelis), was carried out. A pair of diagnostic (1st-look) and surveillance (2nd-look) biopsy were performed per subject (n   =   25), with median interval of 12 months. The documented biopsy-trajectory was used as a target to guide the re-visiting biopsy from the documented @entity5 focus, as well as the targeted field-biopsy from the un-sampled prostatic field adjacent to negative diagnostic biopsies. The accuracy of re-visiting biopsy and biopsy-derived CCP signatures were evaluated in the pair of the serial biopsy-cores. RESULTS: The 1st-look-biopsy revealed a total of 43 @entity5 (1.7 per @entity1 ). The accuracy of re-visiting @entity5 was 86% (37/43) per lesion, 76% (65/86) per core, and 80% (20/25) per @entity1 . This technology also provided an opportunity for 3D-targeted field-biopsy in order to potentially minimize sampling errors. The CCP gene-panel of the 1st-look (-0.59) versus 2nd-look (-0.37) samples had no significant difference (P   =   0.4); which suggested consistency in the molecular signature of the known @entity5 foci during the short-time interval of median 12 months. Any change in CCP of the same @entity5 foci would be likely due to change in sampling location from the less to more significant portion in the @entity5 foci rather than true molecular progression. The study limitations include a small number of the @entity1 . CONCLUSION: The 3D-documented biopsy-mapping technology achieved an encouraging re-sampling accuracy of 86% from the known @entity263 foci, allowing the serial analysis of biopsy-derived CCP signatures. Prostate    2015 Wiley Periodicals, Inc.
